01
Verified capability
Equecabtagene autoleucel (BCMA CAR-T) received official approval in China for adults with relapsed/refractory multiple myeloma after ≥3 prior lines.
Chinese reference name: 血液肿瘤与细胞治疗
Verified cellular immunotherapy (CAR-T) and complex allogeneic hematopoietic transplantation pathways for relapsed or refractory hematologic malignancies in top Chinese tertiary centers.
Explore Related Clinical Specialties
Begin with Hematology, then compare the support departments that can affect diagnosis, intervention, and recovery planning.
These links organize research only. They do not diagnose, refer, or confirm current case acceptance.
Benchmark your condition, review clinical records needed for triage, and prepare your medical travel plan with leading centers.
Pre-selects Ruijin Hospital, Shanghai Jiao Tong University & relevant clinical criteria
Explore clinical indications, treatment modalities, bed and ICU requirements, and patient eligibility criteria verified across leading tertiary centers.
复发/难治多发性骨髓瘤
Target Stage & Goal: For patients with multiple myeloma who have progressed after ≥3 lines of prior therapy (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody). Goal: Deep MRD-negative molecular remission.
Class-10,000 sterile laminar-flow transplant wards (35+ beds), specialized leukapheresis lab, 24/7 dedicated Hematology ICU for rapid CRS/ICANS emergency rescue, national GMP-grade cell preparation qualification.
Equecabtagene Autoleucel (伊基奥仑赛 BCMA CAR-T, Fucaso) & Autologous Stem Cell Rescue.
Diagnosed RRMM after ≥3 prior lines; ECOG 0-1; absolute lymphocyte count ≥0.5×10^9/L; CrCl ≥40 mL/min; LVEF ≥45%; no active uncontrolled systemic infection.
National Rare Diseases Diagnosis and Treatment Network Lead Center, specialized plasma-cell disorder MDT board, high-resolution immunofixation and mass spectrometry laboratories.
Novel dual-target BCMA/CD19 sequential CAR-T protocols & salvage alkylator-free bridging regimens.
Documented extramedullary relapse, high-risk cytogenetics (del(17p), t(4;14), 1q21 amp); adequate bone marrow cellularity for apheresis.
复发/难治弥漫大B细胞淋巴瘤
Target Stage & Goal: Aggressive CD19+ B-cell lymphoma refractory to first-line R-CHOP or relapsed within 12 months post-autologous stem cell transplantation.
Designated commercial infusion center for both Axi-cel and Relma-cel; full-process electronic tracking from vein-to-vein; dedicated cellular therapy clinical coordinator.
Relmacabtagene Autoleucel (瑞基奥仑赛 Carteyva) & Axicabtagene Ciloleucel (阿基仑赛 Yescarta).
Histologically verified CD19+ DLBCL, primary refractory or progressed after ≥2 lines of systemic chemoimmunotherapy; ECOG 0-1.
Full-time bilingual oncologists and hematologists, dedicated single-patient HEPA-filtered cell therapy inpatient floor, direct international commercial insurance direct billing, overseas medical visa invitation support.
Commercial CD19 CAR-T Infusion Fast-Track & Autologous Stem Cell Mobilization.
Overseas or bilingual patients with CD19+ high-grade B-cell lymphoma; stable cardiopulmonary function; manageable tumor burden suitable for fludarabine/cyclophosphamide lymphodepletion.
复发/难治急性淋巴细胞白血病
Target Stage & Goal: B-cell acute lymphoblastic leukemia (B-ALL) with morphologic relapse or persistent minimal residual disease (MRD+ ≥0.01%) post-consolidation.
Ultra-sensitive 10-color flow cytometry minimal residual disease (MRD) detection lab (sensitivity 10^-5), Class-100 sterile isolation transplant rooms, bridging haploidentical transplantation pipeline.
CD19 / CD22 targeted CAR-T cell infusion followed by consolidative allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
Relapsed/refractory B-cell ALL; bone marrow blast count <30% before lymphodepletion; adequate organ reserve; no severe active GVHD.
急性髓系白血病与高危MDS
Target Stage & Goal: Unfavorable-risk cytogenetic/molecular AML (FLT3-ITD, TP53, complex karyotype) or induction failure requiring targeted therapy and immediate transplantation.
NGS-based comprehensive 100+ gene myeloid mutation profiling (FLT3-ITD/TKD, NPM1, IDH1/2, TP53), Asia's largest haploidentical transplant database.
Precision targeted regimens (Venetoclax + Azacitidine, Gilteritinib) combined with haploidentical or matched unrelated Allo-HSCT.
High-risk cytogenetic/molecular AML or induction failure; patient age <70; HCT-CI ≤3; documented absence of active fungal infection.
复杂异基因造血干细胞移植
Target Stage & Goal: Severe hematologic diseases requiring allogeneic stem cell reconstitution with haploidentical family donors or cord blood bridging.
50+ continuous positive-pressure HEPA laminar airflow transplant rooms, specialized post-transplant infection isolation unit, advanced extracorporeal photopheresis (ECP) for refractory GVHD.
Modified Beijing Protocol Haploidentical Transplantation, matched unrelated donor (MUD) transplant, and cord blood salvage transplantation.
High-risk hematologic malignancy in complete remission; HLA-typing completed for patient and potential family donors; negative viral screen for active hepatitis/HIV.
CLDN18.2 Advanced Gastric / GEJ Adenocarcinoma
Target Stage & Goal: Metastatic gastric or gastroesophageal junction adenocarcinoma with confirmed CLDN18.2 overexpression after failure of standard chemotherapy.
Standardized IHC 28-8 CLDN18.2 pathology testing lab, dedicated gastrointestinal oncology multidisciplinary team, intensive monitoring protocol for delayed mucosal and systemic toxicities.
Satricabtagene Autoleucel (CT041 / CLDN18.2-targeted CAR-T) under strict clinical pathway.
Histologically confirmed advanced gastric/GEJ adenocarcinoma; positive CLDN18.2 expression (≥2+ in ≥40% cells); failed ≥2 prior lines; no bowel obstruction or massive ascites.
When This Option May Not Be Suitable
Please evaluate these critical clinical exclusions before initiating cross-border medical consultations.
Documented regulatory approvals, published clinical evidence, and capability standards verified across leading medical centers.
01
Verified capability
Equecabtagene autoleucel (BCMA CAR-T) received official approval in China for adults with relapsed/refractory multiple myeloma after ≥3 prior lines.
02
Verified capability
China has the world's largest and most active cell therapy trial landscape, with standardized clinical pathways across designated Grade 3A teaching centers.
03
Verified international access
Official patient dossiers document international patient admission and successful CAR-T cell manufacturing at Ruijin Hospital and Jiahui International.
Hospitals verified for clinical capability, advanced technology access, and international patient coordination pathways.
01
Documented capability
Leading national hematology center with full-cycle cell therapy manufacturing, infusion, ICU escalation, and bone marrow transplantation.
International access
Verified international medical department (VIP Clinic) supporting English medical records review, case coordinator, and hospital deposit procedures.
Current editorial status
Direct medical intake available. Requires pre-travel submission of complete pathology slides, bone marrow flow cytometry, and prior regimen logs.
Relapsed or refractory multiple myeloma (≥3 prior lines)
Clinical Feature: NMPA approved commercial product, 96% overall response rate, full-trajectory CRS/ICANS ICU monitoring.
Relapsed/refractory large B-cell lymphoma (DLBCL) & follicular lymphoma
Clinical Feature: Designated infusion center with standardized leukapheresis, bridging chemotherapy, and long-term follow-up.
High-risk acute myeloid leukemia (AML) & acute lymphoblastic leukemia (ALL)
Clinical Feature: Advanced sterile laminar flow transplant ward cluster with specialized GVHD prevention and control protocols.
02
Documented capability
Comprehensive international oncology and cell therapy center with bilingual care teams and direct commercial insurance billing.
International access
Publicly verified direct international office (+852 4619 1904 / internationaloffice@jiahui.com) with remote multidisciplinary tumor board review.
Current editorial status
Active intake for international patients. Provides itemized formal medical quotes and medical visa assistance.
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Clinical Feature: Dedicated international inpatient floor, full-time English-speaking hematologists, overseas medical visa invitation letters.
High-dose consolidation for multiple myeloma and sensitive lymphomas
Clinical Feature: Class-100 clean ward environment with comprehensive supportive care and cross-border continuity planning.
03
Documented capability
National benchmark for complex and rare hematologic diseases, systemic clonal disorders, and multiorgan involvement.
International access
English-speaking International Medical Services (IMS) provides outpatient appointments, inpatient care, and remote second opinions.
Current editorial status
Intake through International Medical Services. High case-complexity threshold; requires comprehensive prior diagnostics in English.
Castleman disease, primary CNS lymphoma, refractory plasma cell disorders
Clinical Feature: National Rare Diseases Diagnosis and Treatment Network lead institution; comprehensive multidisciplinary diagnosis (MDT).
Acute leukemias and residual disease eradication planning
Clinical Feature: High-dimensional 10-color flow cytometry and high-throughput NGS deep clonal tracking.
04
Documented capability
Specialized outpatient screening, remote case triaging, and bidirectional transfer partnership with top public hematology wards.
International access
Direct international concierge (+86 400 186 2116 / internationalcare@suh.cn) providing multilingual communication.
Current editorial status
Recommended as an international screening entry point for patients needing translation and liaison with public hospital specialists.
International patients seeking cell therapy candidacy assessment in China
Clinical Feature: Bilingual oncologist first-opinion, digital DICOM / pathology forwarding to tertiary hospital professors.
Contact first, transmit identifiable medical records only through authorized hospital coordination desks.
Having translated clinical records organized accelerates multidisciplinary evaluation and enables accurate treatment feasibility confirmation.
Original pathology paraffin blocks or high-resolution digital slide scans
Bone marrow biopsy morphology, 10-color flow cytometry, cytogenetic FISH, and NGS panel reports
Chronological log of all prior lines: drug regimens, exact dosages, duration, best response, and resistance reasons
Whole-body PET-CT or contrast CT/MRI within the last 30 days (original DICOM disc files)
Organ baseline reserve: Complete blood count, liver/renal panel, coagulation, cardiac echocardiogram (LVEF), and pulmonary PFT
Infectious disease screen: Quantitative HBV DNA, HCV RNA, HIV, CMV, and EBV PCR titers
Performance status documentation: ECOG score and home-country hematologist referral letter
Documented Overall Cost Range & Benchmarks
Commercial CAR-T product cost in China is approximately 990,000 to 1,200,000 RMB. Total pathway cost including hospital stay, lymphodepletion, and CRS management typically ranges from 1.2M to 1.5M RMB in public centers, higher in private international hospitals.
Product drug price must not be confused with the total medical pathway cost. Complications, prolonged cytopenia, ICU care, and blood products will add to the final hospital bill.
Scope: Comprehensive multidisciplinary tumor board review, bone marrow flow cytometry/MRD re-testing, baseline organ workup, leukapheresis machine run, and outpatient bridging medication.
Financial Notes: Typically self-funded deposit or covered by international private health insurance; varies if bridging chemotherapy is needed.
Scope: Commercial CAR-T pharmaceutical purchase (e.g. Equecabtagene Autoleucel / Relmacabtagene Autoleucel) or trial-protocol cell laboratory production.
Financial Notes: Fixed commercial manufacturer price in China (approx. 990,000 - 1,200,000 RMB for commercial products); separate from hospital clinical services.
Scope: Flu/Cy lymphodepleting chemotherapy, sterile laminar ward stay (typically 14-21 days), daily IL-6/cytokine tracking, tocilizumab/steroid CRS intervention, and potential ICU escalation.
Financial Notes: Variable depending on the severity of Cytokine Release Syndrome (CRS) or neurotoxicity (ICANS); patients must reserve an ICU safety buffer.
Scope: Day-30 and Day-90 bone marrow and PET-CT evaluations, immunoglobulin replacement infusions, antiviral prophylaxis, and formal English discharge summary translation.
Financial Notes: Outpatient visits and imaging; long-term infection monitoring transitions to the patient's home-country hematologist.
Essential travel considerations, hospital stay durations, and follow-up safety protocols verified for international patients.
Treatment-specific eligibility, product availability, complication capacity, total pathway cost, and cross-border follow-up Our planning engine benchmarks your medical records, outlines expected cost ranges, and prepares pre-travel intake questions for hospital international desks.
This overview is for medical planning and hospital matching. It does not replace individualized diagnosis by treating specialists. Final treatment plans, drug indications, and quotes must be issued directly by the admitting hospital.